Pair page
BPC-157 with Hexarelin
Mechanism-tag overlap and published literature for BPC-157 and Hexarelin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
cytoprotectiontissue-repair
ghrpgrowth-hormone-releasing-peptide
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying BPC-157 and Hexarelin have published these mechanism-level observations. Not a co-administration recommendation.
Pairs for tissue repair + GH-axis support, particularly in injury recovery protocols. BPC-157's local VEGFR2/NO mechanism complements hexarelin's systemic GH pulse.
Quick facts
BPC-157
Hexarelin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | BPC-157 | Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (544 articles screened, 36 studies included — the single most comprehensive systematic revie… PMID 40756949 | systematic review |
| — | BPC-157 | ClinicalTrials.gov. Study of PL 14736 in Subjects With Ulcerative Colitis. NCT05765058. | human trial |
| 2025 | BPC-157 | Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. PMID 40131143 | human pilot |
| 2024 | BPC-157 | Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. | human pilot |
| 2020 | BPC-157 | Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. (Independent safety study in mice, rats, rabbits, and dogs — no LD1 identifie… | preclinical, in vivo |
| 2006 | BPC-157 | Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. PMID: 16583442. PMID 16583442 | preclinical, in vivo |
| 2003 | BPC-157 | Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208. PMID 14554208 | preclinical, in vivo |
| 2025 | BPC-157 | McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. PMID 40789979 | review |
| 2025 | BPC-157 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| — | BPC-157 | USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org. | regulatory / registry |
| 2025 | BPC-157 | Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. PMID 40005999 | research article |
| 2022 | BPC-157 | Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID: 34380875. PMID 34380875 | research article |
| 2004 | Hexarelin | Frieboes RM, Antonijevic IA, Held K, Murck H, Pollmächer T, Schuld A, Steiger A. Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. Psychoneuroendocrinology. 2004;29(6):728-739. PMID: 15177700. PMID 15177700 | human study |
| 2003 | Hexarelin | Broglio F, Gottero C, Benso A, Prodam F, Destefanis S, Gauna C, Maccario M, Deghenghi R, van der Lely AJ, Ghigo E. Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. J Clin Endocrinol Metab. 2003;88(9):4268-4272. PM… PMID 12970297 | human study |
| 1999 | Hexarelin | Popovic V, Damjanovic S, Micic D, Djurovic M, Petakov M, Dieguez C, Casanueva FF. Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test. J Clin Endocrinol… PMID 10443652 | human study |
| 1999 | Hexarelin | Giordano R, Picu A, Broglio F, Bonelli L, Baldi M, Berardelli R, Ghigo E, Arvat E. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486. J Endocrinol Invest. 1999;22(9):617-622. PMID: 10516483. PMID 10516483 | human study |
| 1994 | Hexarelin | Imbimbo BP, Mant T, Edwards M, Amin D, Dalton N, Boutignon F, Lenaerts V, Wüthrich P, Deghenghi R. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol. 1994;46(5):421-425. PMID: 7957536. PMID 7957536 | human study |
| 2000 | Hexarelin | Torsello A, Locatelli V, Melis MR, Succu S, Spano MS, Deghenghi R, Müller EE, Argiolas A. Differential orexigenic effects of hexarelin and its analogs in the rat hypothalamus: indication for multiple growth hormone secretagogue receptor subtypes. Neuroendocrinology. 2000;72(6):3… PMID 11146416 | preclinical, in vivo |
| 1999 | Hexarelin | Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, Deghenghi R, Müller EE, Berti F. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-4031. PMID: 10465271. PMID 10465271 | preclinical, in vivo |
| 2026 | Hexarelin | WADA. 2026 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. | regulatory / registry |
| 2004 | Hexarelin | Demers A, McNicoll N, Febbraio M, Servant M, Marleau S, Silverstein R, Ong H. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J. 2004;382(Pt 2):417-424. PMID: 15285719. PMID 15285719 | research article |
| 2002 | Hexarelin | Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-849. PMID: 11988484. PMID 11988484 | research article |
| 2000 | Hexarelin | Chen C. Growth hormone secretagogue actions on the pituitary gland: multiple receptors for multiple ligands? Clin Exp Pharmacol Physiol. 2000;27(5-6):323-329. PMID: 10779119. PMID 10779119 | research article |
| 1999 | Hexarelin | Imbimbo BP, Greco F, Marchiaro F, Mantovani V, Rocchi R, Ongini E. The effects of dose, nutrition, and age on hexarelin-induced anterior pituitary hormone secretion in adult patients on maintenance hemodialysis. Nephron. 1999;82(2):147-156. PMID: 10199757. PMID 10199757 | research article |
Related pair pages
More research context
Frequently asked
Have BPC-157 and Hexarelin been studied together?
Researchers have published mechanistic-level co-administration discussion of BPC-157 and Hexarelin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do BPC-157 and Hexarelin share?
BPC-157 and Hexarelin do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of BPC-157 and Hexarelin?
BPC-157: Category 2 (reclassification pending). Hexarelin: Not approved; Category 2. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on BPC-157 and Hexarelin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the BPC-157 profile and the Hexarelin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026